Treace Medical Concepts (NASDAQ:TMCI) CEO John Treace Acquires 39,944 Shares

Treace Medical Concepts, Inc. (NASDAQ:TMCI) CEO John Treace purchased 39,944 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The shares were bought at an average price of $4.44 per share, with a total value of $177,351.36. Following the completion of the acquisition, the chief executive officer owned 7,388,383 shares of the company’s stock, valued at $32,804,420.52. This trade represents a 0.54% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Treace Medical Concepts Stock Up 0.7%

Treace Medical Concepts stock traded up $0.03 during trading hours on Monday, hitting $4.37. The company had a trading volume of 330,428 shares, compared to its average volume of 741,496. Treace Medical Concepts, Inc. has a fifty-two week low of $1.17 and a fifty-two week high of $7.78. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.90 and a quick ratio of 1.95. The firm has a market capitalization of $284.20 million, a P/E ratio of -4.70 and a beta of 1.37. The firm’s fifty day moving average is $4.35 and its 200-day moving average is $2.89.

Treace Medical Concepts (NASDAQ:TMCI) last issued its earnings results on Friday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.06. Treace Medical Concepts had a negative net margin of 28.99% and a negative return on equity of 71.37%. The company had revenue of $45.38 million during the quarter, compared to analyst estimates of $44.02 million. On average, research analysts forecast that Treace Medical Concepts, Inc. will post -0.83 earnings per share for the current year.

Institutional Trading of Treace Medical Concepts

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Graham Capital Management L.P. bought a new stake in shares of Treace Medical Concepts during the 4th quarter worth about $27,000. Osaic Holdings Inc. lifted its holdings in Treace Medical Concepts by 328.3% in the 2nd quarter. Osaic Holdings Inc. now owns 4,793 shares of the company’s stock worth $28,000 after purchasing an additional 3,674 shares during the last quarter. HighTower Advisors LLC acquired a new stake in Treace Medical Concepts in the 4th quarter worth approximately $33,000. Chicago Partners Investment Group LLC boosted its position in Treace Medical Concepts by 34.0% during the first quarter. Chicago Partners Investment Group LLC now owns 26,014 shares of the company’s stock worth $35,000 after purchasing an additional 6,606 shares during the period. Finally, Hsbc Holdings PLC grew its holdings in Treace Medical Concepts by 26.8% during the first quarter. Hsbc Holdings PLC now owns 30,994 shares of the company’s stock valued at $40,000 after purchasing an additional 6,554 shares during the last quarter. Institutional investors and hedge funds own 84.08% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Wall Street Zen raised Treace Medical Concepts from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Truist Financial boosted their price target on Treace Medical Concepts from $4.00 to $5.00 and gave the company a “hold” rating in a research note on Monday, August 10th. Finally, Weiss Ratings downgraded Treace Medical Concepts from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $5.17.

About Treace Medical Concepts

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.